TScan Therapeutics (TCRX): Two 2024 TCR-T Data Readouts Could Bring Significant Value
fatido/iStock via Getty Images TScan Therapeutics (NASDAQ:TCRX) has been able to report positive results from its phase 1 multi-arm study for the treatment of patients with several types of hematological…